Pub Date : 2023-03-01DOI: 10.35479/ijretina.2023.vol006.iss001.223
C. Pius, Thanuja G. Pradeep
Introduction: Idiopathic Intracranial Hypertension (IIH)is defined as increase in intracranial pressure due to unspecified causes leading to headache, papilledema, and transient vision loss. Usually the patients present with mild visual loss but about 25% may develop permanent visual loss due to irreversible optic disc damage. One rare cause of severe visual loss is subretinal hemorrhage (SRH) due to underlying Subretinal Neovascular membrane. Case Report: We report a case of a 36-year-old man diagnosed with IIH and papilloedema with sudden onset profound visual loss in his right eye. On examination, there was a large peripapillary SRH superior to the disc and involving the macula.We stress the importance of recognizing this uncommon complication of papilledema and discuss the possible causes for developing SRH, its most common outcome and the diagnostic as well as treatment modalities available. Discussion: We stress the importance of recognizing this uncommon complication of papilledema and discuss the possible causes for developing SRH, its most common outcome and the diagnostic as well as current treatment modalities available. Conclusion: This report highlights a rare case of spontaneous sub retinal haemorrhage in a patient with IIH. Measurement of optic nerve sheath diameter can be a vital tool for the diagnosis of raised intracranial pressure in this setting.
{"title":"RARE CASE OF SPONTANEOUS SUB-RETINAL HAEMORRHAGE ASSOCIATED WITH IDOPATHIC INTRACRANIAL HYPERTENSION","authors":"C. Pius, Thanuja G. Pradeep","doi":"10.35479/ijretina.2023.vol006.iss001.223","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.223","url":null,"abstract":"Introduction: Idiopathic Intracranial Hypertension (IIH)is defined as increase in intracranial pressure due to unspecified causes leading to headache, papilledema, and transient vision loss. Usually the patients present with mild visual loss but about 25% may develop permanent visual loss due to irreversible optic disc damage. One rare cause of severe visual loss is subretinal hemorrhage (SRH) due to underlying Subretinal Neovascular membrane. \u0000Case Report: We report a case of a 36-year-old man diagnosed with IIH and papilloedema with sudden onset profound visual loss in his right eye. On examination, there was a large peripapillary SRH superior to the disc and involving the macula.We stress the importance of recognizing this uncommon complication of papilledema and discuss the possible causes for developing SRH, its most common outcome and the diagnostic as well as treatment modalities available. \u0000Discussion: We stress the importance of recognizing this uncommon complication of papilledema and discuss the possible causes for developing SRH, its most common outcome and the diagnostic as well as current treatment modalities available. \u0000Conclusion: This report highlights a rare case of spontaneous sub retinal haemorrhage in a patient with IIH. Measurement of optic nerve sheath diameter can be a vital tool for the diagnosis of raised intracranial pressure in this setting.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72540237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.35479/ijretina.2023.vol006.iss001.205
Nizma Permaisuari, Julie D. Barliana
Introduction: The objective of this study was to assess the neurodevelopmental outcomes in preterm infants who have undergone intravitreal anti-vascular endothelial growth factor (anti-VEGF), either as monotherapy or in combination with laser therapy, for treatment of retinopathy of prematurity (ROP). Secondary, efficacy of anti-VEGF was also evaluated. Methods: Literature search was conducted using 7 online databases (CENTRAL, PubMed, ScienceDirect, SCOPUS, EBSCO, ProQuest, and JSTOR). Studies were selected based on the established inclusion and exclusion criteria. Primary outcomes were neurodevelopmental impairment (NDI), severe NDI (sNDI), neurodevelopmental scores, and cerebral palsy (CP) incidence. Secondary outcomes included impairment and severe impairment of each domain (motor, cognitive, and language) and retreatment of ROP. Result: Seventeen studies were included. Random-effects model meta-analysis showed no differences were observed between anti-VEGF compared to control group in NDI (unadjusted odds ratio (uOR) 1.28; 95% confidence interval (CI) 0.85 to 1.94), sNDI (uOR 1.33; 95% CI 0.92 to 1.93), and CP outcomes . Meta-analysis showed insignificant result with lower overall scores, motor, cognitive, and language domains associated with anti-VEGF treatment. Secondary outcomes showed inferior cognitive impairment (OR 1.41; 95% CI: 1.03 to 1.92) and higher retreatment rate (OR 47.55; 95% CI: 12.35 to 183.09) in anti-VEGF group. Conclusion: There were no differences in neurodevelopmental outcomes between anti-VEGF and control group. Despite not causing any adverse neurodevelopmental effect, clinicians should carefully weigh the benefits and risks of anti-VEGF injection for treating infants with ROP, since it has higher retreatment rate.
{"title":"NEURODEVELOPMENTAL OUTCOMES AFTER ANTI-VEGF TREATMENT FOR RETINOPATHY OF PREMATURITY: A SYSTEMATIC REVIEW AND META-ANALYSIS","authors":"Nizma Permaisuari, Julie D. Barliana","doi":"10.35479/ijretina.2023.vol006.iss001.205","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.205","url":null,"abstract":"Introduction: The objective of this study was to assess the neurodevelopmental outcomes in preterm infants who have undergone intravitreal anti-vascular endothelial growth factor (anti-VEGF), either as monotherapy or in combination with laser therapy, for treatment of retinopathy of prematurity (ROP). Secondary, efficacy of anti-VEGF was also evaluated. \u0000Methods: Literature search was conducted using 7 online databases (CENTRAL, PubMed, ScienceDirect, SCOPUS, EBSCO, ProQuest, and JSTOR). Studies were selected based on the established inclusion and exclusion criteria. Primary outcomes were neurodevelopmental impairment (NDI), severe NDI (sNDI), neurodevelopmental scores, and cerebral palsy (CP) incidence. Secondary outcomes included impairment and severe impairment of each domain (motor, cognitive, and language) and retreatment of ROP. \u0000Result: Seventeen studies were included. Random-effects model meta-analysis showed no differences were observed between anti-VEGF compared to control group in NDI (unadjusted odds ratio (uOR) 1.28; 95% confidence interval (CI) 0.85 to 1.94), sNDI (uOR 1.33; 95% CI 0.92 to 1.93), and CP outcomes . Meta-analysis showed insignificant result with lower overall scores, motor, cognitive, and language domains associated with anti-VEGF treatment. Secondary outcomes showed inferior cognitive impairment (OR 1.41; 95% CI: 1.03 to 1.92) and higher retreatment rate (OR 47.55; 95% CI: 12.35 to 183.09) in anti-VEGF group. \u0000Conclusion: There were no differences in neurodevelopmental outcomes between anti-VEGF and control group. Despite not causing any adverse neurodevelopmental effect, clinicians should carefully weigh the benefits and risks of anti-VEGF injection for treating infants with ROP, since it has higher retreatment rate.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85190707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.35479/ijretina.2023.vol006.iss001.226
Sita Paramita Ayuningtyas, A. Djatikusumo, S. Nusanti, Salmarezka Dewiputri, M. Sidik
Introduction: Dapsone has been widely used as a part of multidrug therapy for leprosy patients. Ocular side effects are rare. Ocular toxicity manifestations include retinal necrosis, optic atrophy, macular infarction, bilateral exudative retinal detachment, and choroidal detachment. We reported a rare case of dapsone-induced toxic maculopathy in a leprosy patient. Case Report: A 32-year-old male complained of blurred vision and a gray spot in central vision in the left eye (LE) for one month prior to admission. He had been treated with multidrug therapy (MDT) for leprosy for seven months. The MDT consists of dapsone, clofazimine, and rifampicin. The best-corrected visual acuity (BCVA) of the right eye (RE) and the LE were 6/6 and 6/12, respectively. A funduscopy of the LE showed decreased macular reflex. A color vision defect following the tritan axis was found in the LE. The Humphrey visual field (HVF) test of the LE revealed a central scotoma. Macular optical coherence tomography (OCT) showed intraretinal hyperreflectivity and subretinal fluid. Dapsone was then stopped in collaboration with a dermatologist. Two months after the discontinuation of Dapsone, the BCVA of the LE improved to 6/7.5, then 6/6 three months later. Color vision, macular OCT, and HVF tests revealed improvements. Multifocal ERG of both eyes (BE) also showed improvement in N1 and P1 wave amplitude in both eyes on 9-month follow-up after dapsone discontinuation. Discussion: Instead of direct drug toxicity, the mechanism of ocular side effects is thought to be ischemia caused by two distinct mechanisms. Macular ischemia is caused by acute, severe peripheral hypoxia and the physical effect of red cell fragmentation due to the hemolytic process. After discontinuation of dapsone, this case showed improvement in visual function and macular structure. Conclusion: Toxic maculopathy may be present in leprosy patients receiving dapsone treatment, although it is uncommon. Regular follow-up and evaluation of visual function and macular involvement are essential. Early detection of dapsone-induced toxic maculopathy and prompt discontinuation of dapsone may result in an improvement of visual functions.
{"title":"DAPSONE-INDUCED TOXIC MACULOPATHY IN LEPROSY PATIENT","authors":"Sita Paramita Ayuningtyas, A. Djatikusumo, S. Nusanti, Salmarezka Dewiputri, M. Sidik","doi":"10.35479/ijretina.2023.vol006.iss001.226","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.226","url":null,"abstract":"Introduction: Dapsone has been widely used as a part of multidrug therapy for leprosy patients. Ocular side effects are rare. Ocular toxicity manifestations include retinal necrosis, optic atrophy, macular infarction, bilateral exudative retinal detachment, and choroidal detachment. We reported a rare case of dapsone-induced toxic maculopathy in a leprosy patient. \u0000Case Report: A 32-year-old male complained of blurred vision and a gray spot in central vision in the left eye (LE) for one month prior to admission. He had been treated with multidrug therapy (MDT) for leprosy for seven months. The MDT consists of dapsone, clofazimine, and rifampicin. The best-corrected visual acuity (BCVA) of the right eye (RE) and the LE were 6/6 and 6/12, respectively. A funduscopy of the LE showed decreased macular reflex. A color vision defect following the tritan axis was found in the LE. The Humphrey visual field (HVF) test of the LE revealed a central scotoma. Macular optical coherence tomography (OCT) showed intraretinal hyperreflectivity and subretinal fluid. Dapsone was then stopped in collaboration with a dermatologist. Two months after the discontinuation of Dapsone, the BCVA of the LE improved to 6/7.5, then 6/6 three months later. Color vision, macular OCT, and HVF tests revealed improvements. Multifocal ERG of both eyes (BE) also showed improvement in N1 and P1 wave amplitude in both eyes on 9-month follow-up after dapsone discontinuation. \u0000Discussion: Instead of direct drug toxicity, the mechanism of ocular side effects is thought to be ischemia caused by two distinct mechanisms. Macular ischemia is caused by acute, severe peripheral hypoxia and the physical effect of red cell fragmentation due to the hemolytic process. After discontinuation of dapsone, this case showed improvement in visual function and macular structure. \u0000Conclusion: Toxic maculopathy may be present in leprosy patients receiving dapsone treatment, although it is uncommon. Regular follow-up and evaluation of visual function and macular involvement are essential. Early detection of dapsone-induced toxic maculopathy and prompt discontinuation of dapsone may result in an improvement of visual functions.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82529624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.35479/ijretina.2023.vol006.iss001.210
D. Yulia, Marissa Jayawinata, Mario Marbungaran Hutapea
Introduction: Advanced stages of Retinopathy of Prematurity (ROP) could lead to childhood blindness and retinal surgery is needed as the main treatment. This case aims to report the clinical outcomes after surgery for advanced-stage ROP Case Report: A female infant was admitted to the pediatric ophthalmology clinic in Cipto Mangunkusumo National Central Hospital Jakarta with a lack of visual contact in both eyes at 53 weeks of Post Menstrual Age (PMA). The infant was delivered at 28 weeks of gestational age with a birth weight of 1100 g. The baby was treated in NICU for 24 days and received oxygen therapy in the previous hospital. Retinal examination revealed that the patient had stage 5 ROP in the right eye and stage 4B ROP in the left eye. Furthermore, blinking reflect was absent in both eyes. Vitrectomy and endolaser were performed for the baby’s left eye. Surgery was not conducted for the infant’s right eye due to poor prognosis. Six weeks after surgery, the infant underwent examination under anesthesia (EUA) which showed that the retina was reattached with no vitreous hemorrhage, and intraocular pressure measurement was 7 mmHg. The result of the visual acuity test by Cardiff Acuity Cards was 6/60 on both eyes. Followed up EUA reported that the refraction test result on the left eye was S-3.75 C-5.75 x 85o and an undetermined result on the right eye due to opacity in the visual axis. Discussion: Several surgeries have been described as the treatment of choice for advanced-stage ROP, including scleral buckling and vitrectomy with or without the addition of endolaser. Previous studies illustrated that stage 5 ROP has a low success rate on lens-sparing vitrectomy compared to stage 4A and 4B. The outcome success rate was the best in stage 4A ROP. Moreover, stage 4B ROP had a moderate success rate with sufficient visual outcomes. Conclusion: The functional outcome of vitrectomy surgery may not equate to anatomic success. Retinal reattachment and moderate visual outcome were achieved by performing vitrectomy and endolaser in this case. Followed-up periodically is necessary for advanced stage ROP postoperatively.
早产儿视网膜病变(ROP)的晚期可导致儿童失明，视网膜手术是主要的治疗方法。本病例旨在报告晚期ROP手术后的临床结果病例报告:一名女婴在经后年龄(PMA) 53周时因双眼缺乏视觉接触而被送入雅加达Cipto Mangunkusumo国立中心医院的儿童眼科诊所。婴儿在28周孕龄时出生，出生体重为1100克。患儿在新生儿重症监护病房治疗24天，并在原医院吸氧治疗。视网膜检查显示患者右眼ROP为5期，左眼ROP为4B期。两眼均无闪烁反射。对婴儿左眼行玻璃体切除术和激光手术。由于预后不佳，未对该婴儿的右眼进行手术。术后6周，患儿行麻醉检查(EUA)，视网膜重新附着，无玻璃体出血，眼压7 mmHg。卡迪夫视力卡视力测试结果为双眼6/60。随访EUA报告左眼屈光测试结果为S-3.75 C-5.75 x 85，右眼由于视轴不透明，结果不确定。讨论:几种手术已经被描述为晚期ROP的治疗选择，包括巩膜扣合和玻璃体切除术，有或没有增加激光。先前的研究表明，与4A期和4B期相比，5期ROP在保留晶状体的玻璃体切除术中成功率较低。4A期ROP的预后成功率最高。此外，4B期ROP有中等的成功率和足够的视觉效果。结论:玻璃体切割手术的功能结果不一定等同于解剖上的成功。通过玻璃体切除术和激光治疗，视网膜复位和视力达到了中等水平。晚期ROP术后定期随访是必要的。
{"title":"CLINICAL OUTCOMES OF SURGERY FOR ADVANCED STAGE RETINOPATHY OF PREMATURITY: A CASE REPORT","authors":"D. Yulia, Marissa Jayawinata, Mario Marbungaran Hutapea","doi":"10.35479/ijretina.2023.vol006.iss001.210","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.210","url":null,"abstract":"Introduction: Advanced stages of Retinopathy of Prematurity (ROP) could lead to childhood blindness and retinal surgery is needed as the main treatment. This case aims to report the clinical outcomes after surgery for advanced-stage ROP \u0000Case Report: A female infant was admitted to the pediatric ophthalmology clinic in Cipto Mangunkusumo National Central Hospital Jakarta with a lack of visual contact in both eyes at 53 weeks of Post Menstrual Age (PMA). The infant was delivered at 28 weeks of gestational age with a birth weight of 1100 g. The baby was treated in NICU for 24 days and received oxygen therapy in the previous hospital. Retinal examination revealed that the patient had stage 5 ROP in the right eye and stage 4B ROP in the left eye. Furthermore, blinking reflect was absent in both eyes. Vitrectomy and endolaser were performed for the baby’s left eye. Surgery was not conducted for the infant’s right eye due to poor prognosis. Six weeks after surgery, the infant underwent examination under anesthesia (EUA) which showed that the retina was reattached with no vitreous hemorrhage, and intraocular pressure measurement was 7 mmHg. The result of the visual acuity test by Cardiff Acuity Cards was 6/60 on both eyes. Followed up EUA reported that the refraction test result on the left eye was S-3.75 C-5.75 x 85o and an undetermined result on the right eye due to opacity in the visual axis. \u0000Discussion: Several surgeries have been described as the treatment of choice for advanced-stage ROP, including scleral buckling and vitrectomy with or without the addition of endolaser. Previous studies illustrated that stage 5 ROP has a low success rate on lens-sparing vitrectomy compared to stage 4A and 4B. The outcome success rate was the best in stage 4A ROP. Moreover, stage 4B ROP had a moderate success rate with sufficient visual outcomes. \u0000Conclusion: The functional outcome of vitrectomy surgery may not equate to anatomic success. Retinal reattachment and moderate visual outcome were achieved by performing vitrectomy and endolaser in this case. Followed-up periodically is necessary for advanced stage ROP postoperatively.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85356839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-28DOI: 10.35479/ijretina.2023.vol006.iss001.221
Ariani Andayani, I. Made, Dwi Surya Wibawa, Ni Made, Ari Suryathi, Anak Agung, Mas Putrawati Triningrat, Ida Bagus, Putra Manuaba
Introduction: Pars plana vitrectomy with silicone oil injection has become a standard procedure to treat retinal detachment with complex cases. Considerations related to the use of silicone oil are the need for additional surgical procedures to remove silicone oil after the retinal condition is declared stable or because emulsification of silicone oil has occurred. Methods: An analytical observational study with a cross-sectional approach. Data were collected retrospectively by collecting medical records of patients who underwent silicone oil evacuation in 2021. Result: The research subjects were 23 people, where 52.2% of the subjects were women with a median age of 51 years. Most of the subjects (65.2%) had no complications, with the most complications occurring were secondary glaucoma (13%) and redetached retina (13%). There was no statistically significant difference between visual acuity before and after the evacuation of silicone oil with a P value of 0.202 and there was no statistically significant difference between IOP before and after evacuation of silicone oil with a P value of 0.132. Conclusion: Evacuation of silicone oil is a follow-up action after PPV with SO tamponade. Complications which may arise are detach dan glaucoma. There was no significant difference in visual acuity and IOP before and after SO evacuation.
{"title":"POST-EVACUATION OF SILICONE OIL COMPLICATIONS IN RHEGMATOGENOUS RETINAL DETACHMENT PATIENTS WHO UNDERWENT PARS PLANA VITRECTOMY AT TERTIARY HOSPITAL IN BALI, INDONESIA","authors":"Ariani Andayani, I. Made, Dwi Surya Wibawa, Ni Made, Ari Suryathi, Anak Agung, Mas Putrawati Triningrat, Ida Bagus, Putra Manuaba","doi":"10.35479/ijretina.2023.vol006.iss001.221","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.221","url":null,"abstract":"Introduction: Pars plana vitrectomy with silicone oil injection has become a standard procedure to treat retinal detachment with complex cases. Considerations related to the use of silicone oil are the need for additional surgical procedures to remove silicone oil after the retinal condition is declared stable or because emulsification of silicone oil has occurred. \u0000Methods: An analytical observational study with a cross-sectional approach. Data were collected retrospectively by collecting medical records of patients who underwent silicone oil evacuation in 2021. \u0000Result: The research subjects were 23 people, where 52.2% of the subjects were women with a median age of 51 years. Most of the subjects (65.2%) had no complications, with the most complications occurring were secondary glaucoma (13%) and redetached retina (13%). There was no statistically significant difference between visual acuity before and after the evacuation of silicone oil with a P value of 0.202 and there was no statistically significant difference between IOP before and after evacuation of silicone oil with a P value of 0.132. \u0000Conclusion: Evacuation of silicone oil is a follow-up action after PPV with SO tamponade. Complications which may arise are detach dan glaucoma. There was no significant difference in visual acuity and IOP before and after SO evacuation.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84201453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-28DOI: 10.35479/ijretina.2023.vol006.iss001.231
Referano Agustiawan
{"title":"Future Eye Related Disease due to Myopia","authors":"Referano Agustiawan","doi":"10.35479/ijretina.2023.vol006.iss001.231","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.231","url":null,"abstract":"","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82984238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-28DOI: 10.35479/ijretina.2023.vol006.iss001.213
M. Maslik, Y. Abaaqil, S. belghmaidi, I. Hajji, A. Moutaouakil
Introduction: To determine if performing 360° laser retinopexy anterior to the equator during surgery is a viable option to prevent recurrent retinal detachment following a primary pars plana vitrectomy for rhegmatogenous retinal detachment. Methods: A consecutive case series of 142 patients with retinal detachment who underwent vitrectomy by a single surgeon in Mohammed VI university hospital Marrakech hospital between January 2020 and December 2021. A comparison was made between a group of consecutive patients who underwent 360° laser retinopexy and a control group of patients who did not receive the treatment (39). Patient demographic and clinical information was gathered from medical records. Both groups were analyzed and compared in terms of baseline characteristics and the risk of recurrent retinal detachment over time. Result: Prophylactic intraoperative 360° laser treatment was performed on 103 RRD cases (52 years) and compared to a control group of 39 RRD cases (56.8 years). The rate of the incidence of recurrent retinal detachment at six months after surgery was 12.6%( 13/103 eyes) in the 360° laser group and 28.2%(11/ 39 eyes) in the control group. Conclusion: Intraoperative 360° laser retinopexy performed after primary pars plana vitrectomy led to a substantial decrease in the rate of recurrent retinal detachment post-surgery.
{"title":"IS 360° INTRAOPERATIVE LASER RETINOPEXY AFTER PRIMARY PARS PLANA VITRECTOMY WORTHWHILE TO PREVENT RECURRENT RETINAL DETACHMENT?","authors":"M. Maslik, Y. Abaaqil, S. belghmaidi, I. Hajji, A. Moutaouakil","doi":"10.35479/ijretina.2023.vol006.iss001.213","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.213","url":null,"abstract":"Introduction: To determine if performing 360° laser retinopexy anterior to the equator during surgery is a viable option to prevent recurrent retinal detachment following a primary pars plana vitrectomy for rhegmatogenous retinal detachment. \u0000Methods: A consecutive case series of 142 patients with retinal detachment who underwent vitrectomy by a single surgeon in Mohammed VI university hospital Marrakech hospital between January 2020 and December 2021. A comparison was made between a group of consecutive patients who underwent 360° laser retinopexy and a control group of patients who did not receive the treatment (39). Patient demographic and clinical information was gathered from medical records. Both groups were analyzed and compared in terms of baseline characteristics and the risk of recurrent retinal detachment over time. \u0000Result: Prophylactic intraoperative 360° laser treatment was performed on 103 RRD cases (52 years) and compared to a control group of 39 RRD cases (56.8 years). The rate of the incidence of recurrent retinal detachment at six months after surgery was 12.6%( 13/103 eyes) in the 360° laser group and 28.2%(11/ 39 eyes) in the control group. \u0000Conclusion: Intraoperative 360° laser retinopexy performed after primary pars plana vitrectomy led to a substantial decrease in the rate of recurrent retinal detachment post-surgery.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74333615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-28DOI: 10.35479/ijretina.2023.vol006.iss001.227
Reyno Satria Ali, A. Victor, A. Djatikusumo, Gitalisa Andayani, Anggun Rama Yudanta, Mario Marbungaran Hutapea
Introduction: Proliferative Diabetic retinopathy is the most common cause of blindness in adults. In the management of vitreous hemorrhage, vitrectomy is the main choice and also laser photocoagulation with or without anti-VEGF administration as additional therapy. This study aims to determine the number of patients, demographic characteristics, clinics, risk factors, distribution of treatment, and treatment outcomes for PDR patients with vitreous hemorrhage at Cipto Mangunkusumo Hospital. Methods: This study was retrospective descriptive study conducted from January 2020 to October 2022 who met the inclusion criteria. Population in this study were patients at Cipto Mangunkusumo Hospital with PDR accompanied by vitreous hemorrhage. Data shown in the table were mean (standard deviation) and number (percentage) based on the type of the data. Result: A total of 146 patients with the diagnosis of Proliferative Diabetic Retinopathy (PDR) with vitreous hemorrhage. Majority of subjects were men (60,9%), diagnosed with DM more than 10 years (63,0%) with another systemic risk factor. The most common clinical characteristics found visual acuity at the initial visit <3/60 (80,8%), diagnosed phakia (78,9%), retinal detachment (85,3%), grade 2 vitreous hemorrhage (80,8%). The majority of eyes underwent vitrectomy (90,44%), Anti-VEGF injections (22,92%), Laser PRP (11,46 %), Phacoemulsification pre and post- vitrectomy as adjuvant treatment. The condition of the vitreous was clear after vitrectomy (99,1%). Mean visual acuity before vitrectomy is 2.10 (1.80 – 2.50), while mean visual acuity after vitctomy was 1.00 (1.30 – 2.40), with a difference in initial and final visual acuity of -0.10 (-0.50 – 0.60). Conclusion: Majority of study subjects were men with an age range of 25-77 years. Vitrectomy as the main treatment combined with intravitreal injection of anti-VEGF, laser PRP as adjuvant treatment. In nearly all cases, vitreous hemorrhage was clear after vitrectomy treatment. Visual acuity after vitrectomy shows progress even though in some cases there was no improvement.
{"title":"CLINICAL CHARACTERISTICS OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR) PATIENTS WITH VITREOUS HEMORRHAGE AT CIPTO MANGUNKUSUMO HOSPITAL","authors":"Reyno Satria Ali, A. Victor, A. Djatikusumo, Gitalisa Andayani, Anggun Rama Yudanta, Mario Marbungaran Hutapea","doi":"10.35479/ijretina.2023.vol006.iss001.227","DOIUrl":"https://doi.org/10.35479/ijretina.2023.vol006.iss001.227","url":null,"abstract":"Introduction: Proliferative Diabetic retinopathy is the most common cause of blindness in adults. In the management of vitreous hemorrhage, vitrectomy is the main choice and also laser photocoagulation with or without anti-VEGF administration as additional therapy. This study aims to determine the number of patients, demographic characteristics, clinics, risk factors, distribution of treatment, and treatment outcomes for PDR patients with vitreous hemorrhage at Cipto Mangunkusumo Hospital. \u0000Methods: This study was retrospective descriptive study conducted from January 2020 to October 2022 who met the inclusion criteria. Population in this study were patients at Cipto Mangunkusumo Hospital with PDR accompanied by vitreous hemorrhage. Data shown in the table were mean (standard deviation) and number (percentage) based on the type of the data. \u0000Result: A total of 146 patients with the diagnosis of Proliferative Diabetic Retinopathy (PDR) with vitreous hemorrhage. Majority of subjects were men (60,9%), diagnosed with DM more than 10 years (63,0%) with another systemic risk factor. The most common clinical characteristics found visual acuity at the initial visit <3/60 (80,8%), diagnosed phakia (78,9%), retinal detachment (85,3%), grade 2 vitreous hemorrhage (80,8%). The majority of eyes underwent vitrectomy (90,44%), Anti-VEGF injections (22,92%), Laser PRP (11,46 %), Phacoemulsification pre and post- vitrectomy as adjuvant treatment. The condition of the vitreous was clear after vitrectomy (99,1%). Mean visual acuity before vitrectomy is 2.10 (1.80 – 2.50), while mean visual acuity after vitctomy was 1.00 (1.30 – 2.40), with a difference in initial and final visual acuity of -0.10 (-0.50 – 0.60). \u0000Conclusion: Majority of study subjects were men with an age range of 25-77 years. Vitrectomy as the main treatment combined with intravitreal injection of anti-VEGF, laser PRP as adjuvant treatment. In nearly all cases, vitreous hemorrhage was clear after vitrectomy treatment. Visual acuity after vitrectomy shows progress even though in some cases there was no improvement.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75172725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-27DOI: 10.35479/ijretina.2022.vol005.iss002.193
Marsha Rayfa Pintary, A. Djatikusumo, Salmarezka Dewiputri, S. Nusanti, M. Sidik
Introduction: Non-arteritic Ischemic Optic Neuropathy is the most common type of ischemic optic neuropathy. Nearly half of NAION patients presented with 20/30 or better visual acuity. Central vision is often preserved relative to the visual field loss. Macular edema in NAION patient is rare, and its occurrence may confuse to other disease and lead to unnecessary treatment. Case Report: We identified three NAION patients presented with macular edema. The patients' age was above 40 and had diabetes mellitus (DM). Our patients had clinical findings consistent with NAION with poor visual acuity at the early presentation. Optical coherence tomography examination was performed, and all patients had prominent subretinal fluid. Intravitreal anti-VEGF injection was done on our first patient and no treatment was given to our second and third patient. All patients showed a significant improvement of macular edema. Discussion: Macular edema is a rare clinical manifestation that may contribute a visual deterioration in NAION. The incidence of macular edema in NAION patients is difficult to measure since OCT of macula is not routinely performed. In our report, we encountered three cases of NAION complicated by macular edema that underwent a different approach in therapy. Spontaneous regression of subretinal fluid was seen during observation without any treatment given. Our patients achieved a stable visual acuity and visual field defect. This finding is under the literature that spontaneous recovery will be observed during the natural course of acute NAION. Conclusion: Macular edema is an unusual but self-limiting presentation of NAION. Therefore, a comprehensive examination is needed to prevent any unnecessary treatment.
{"title":"Macular Edema as Unusual Presentation of Non-Arteritic Ischemic Optic Neuropathy (NAION)","authors":"Marsha Rayfa Pintary, A. Djatikusumo, Salmarezka Dewiputri, S. Nusanti, M. Sidik","doi":"10.35479/ijretina.2022.vol005.iss002.193","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss002.193","url":null,"abstract":"Introduction: Non-arteritic Ischemic Optic Neuropathy is the most common type of ischemic optic neuropathy. Nearly half of NAION patients presented with 20/30 or better visual acuity. Central vision is often preserved relative to the visual field loss. Macular edema in NAION patient is rare, and its occurrence may confuse to other disease and lead to unnecessary treatment. \u0000Case Report: We identified three NAION patients presented with macular edema. The patients' age was above 40 and had diabetes mellitus (DM). Our patients had clinical findings consistent with NAION with poor visual acuity at the early presentation. Optical coherence tomography examination was performed, and all patients had prominent subretinal fluid. Intravitreal anti-VEGF injection was done on our first patient and no treatment was given to our second and third patient. All patients showed a significant improvement of macular edema. \u0000Discussion: Macular edema is a rare clinical manifestation that may contribute a visual deterioration in NAION. The incidence of macular edema in NAION patients is difficult to measure since OCT of macula is not routinely performed. In our report, we encountered three cases of NAION complicated by macular edema that underwent a different approach in therapy. Spontaneous regression of subretinal fluid was seen during observation without any treatment given. Our patients achieved a stable visual acuity and visual field defect. This finding is under the literature that spontaneous recovery will be observed during the natural course of acute NAION. \u0000Conclusion: Macular edema is an unusual but self-limiting presentation of NAION. Therefore, a comprehensive examination is needed to prevent any unnecessary treatment.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80601014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-27DOI: 10.35479/ijretina.2022.vol005.iss002.124
Dicky Budiman Simanjuntak, A. Victor, Gitalisa Andayani
Introduction: Chorioretinal coloboma (CRC) results from abnormal closure of the embryonic fissure. Choroidal neovascularization (CNV) is a rare complication that associated with coloboma of the choroid. VEGF is an important factor in the development of CNV. Case Report: A 52-year-old woman with gradual blurred vision of the left eye since 4 months ago. Right eye was already blurred since she was a child with uncorrected visual acuity (UCVA) was 0.5/60. Her right iris showed coloboma in inferior and chorioretinal coloboma. UCVA of the left eye was 6/20. Her left iris showed inferior coloboma, chorioretinal coloboma and macular edema with soft drusen. Macular optical coherence tomography (OCT) confirmed macular subretinal fluid, and indicated a CNV lesion of the left eye. She underwent a loading dose of three monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections (bevacizumab) for the left eye. One month after completion of treatment, UCVA of the left eye improved to 6/12. Discussion: CNV is a complication associated with CRC. Intravitreal Anti-VEGF treatment using loading dose regimen is shown to be effective in treating CNV. One month after completion of treatment, UCVA of the left eye improved. Conclusion: Chorioretinal coloboma is a rare posterior segment congenital anomaly. Classical, bilateral coloboma of the choroid and iris indicates a deformation of the choroidal fissure closure. Coloboma of the choroid can have a complication such as choroidal neovascularization. Treatment with a loading dose of three monthly intravitreal anti-VEGF injections showed good anatomical and functional results.
{"title":"CHOROIDAL NEOVASCULARIZATION IN A CASE OF CHORIORETINAL COLOBOMA TREATED WITH INTRAVITREAL ANTI-VEGF INJECTONS: A CASE REPORT","authors":"Dicky Budiman Simanjuntak, A. Victor, Gitalisa Andayani","doi":"10.35479/ijretina.2022.vol005.iss002.124","DOIUrl":"https://doi.org/10.35479/ijretina.2022.vol005.iss002.124","url":null,"abstract":"Introduction: Chorioretinal coloboma (CRC) results from abnormal closure of the embryonic fissure. Choroidal neovascularization (CNV) is a rare complication that associated with coloboma of the choroid. VEGF is an important factor in the development of CNV. \u0000Case Report: A 52-year-old woman with gradual blurred vision of the left eye since 4 months ago. Right eye was already blurred since she was a child with uncorrected visual acuity (UCVA) was 0.5/60. Her right iris showed coloboma in inferior and chorioretinal coloboma. UCVA of the left eye was 6/20. Her left iris showed inferior coloboma, chorioretinal coloboma and macular edema with soft drusen. Macular optical coherence tomography (OCT) confirmed macular subretinal fluid, and indicated a CNV lesion of the left eye. She underwent a loading dose of three monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections (bevacizumab) for the left eye. One month after completion of treatment, UCVA of the left eye improved to 6/12. \u0000Discussion: CNV is a complication associated with CRC. Intravitreal Anti-VEGF treatment using loading dose regimen is shown to be effective in treating CNV. One month after completion of treatment, UCVA of the left eye improved. \u0000Conclusion: Chorioretinal coloboma is a rare posterior segment congenital anomaly. Classical, bilateral coloboma of the choroid and iris indicates a deformation of the choroidal fissure closure. Coloboma of the choroid can have a complication such as choroidal neovascularization. Treatment with a loading dose of three monthly intravitreal anti-VEGF injections showed good anatomical and functional results.","PeriodicalId":33128,"journal":{"name":"IJRETINA International Journal of Retina","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91108295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：